# US 2015/0148367 A1 · Controlled release hydrocodone formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148367 A1
- Document ID: US20150148367A1
- Status: Published application
- Kind: A1
- Application number: 14/612,483
- Filed: 2015-02-03
- Published: 2015-05-28
- Earliest claimed: 2000-10-30
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Benjamin Oshlack; Hua-Pin Huang; John K. Masselink; Alfred Tonelli
- Web page: https://patentgrep.com/patent/US20150148367A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/141: {Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products A61K9/16, (co) lyophilised products A61K9/19; the carrier being chemically bound to the active ingredient A61K47/50)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

## Claims

### Claim at position 1

1-38. (canceled)

### Claim 39

A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a matrix comprising hydrocodone or a pharmaceutically acceptable salt thereof, a controlled release material and hydroxypropylcellulose or hydroxypropylmethylcellulose, such that the dosage form provides a ratio of a plasma concentration of hydrocodone at the end of a dosing interval to a maximum plasma concentration of hydrocodone during the dosing interval of about 0.55 to about 1 and an effective pain relief over a period of time of about 12 hours or longer after administration to a human patient, wherein
the dosage form is a compressed tablet,
the amount of hydrocodone in the dosage form is from about 0.5 mg to about 1250 mg, and
the hydrocodone or pharmaceutically acceptable salt thereof is the only active agent in the dosage form.

### Claim 40 (depends on 39)

The dosage form of claim 39, wherein the effective pain relief is provided for about 12 hours.

### Claim 41 (depends on 40)

The dosage form of claim 40, wherein said administration is first administration.

### Claim 42 (depends on 41)

The dosage form of claim 41, wherein the controlled release material comprises a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac, and oils.

### Claim 43

A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a matrix comprising hydrocodone or a pharmaceutically acceptable salt thereof, a controlled release material and hydroxypropylcellulose or hydroxypropylmethylcellulose, such that the dosage form provides a W50 of hydrocodone of between 4 and 22 hours and a plasma concentration of hydrocodone within a therapeutic range but below toxic concentrations over a period of time of about 12 hours or longer after administration to a human patient, wherein
the dosage form is a compressed tablet,
the amount of hydrocodone in the dosage form is from about 0.5 mg to about 1250 mg, and
the hydrocodone or pharmaceutically acceptable salt thereof is the only active agent in the dosage form.

### Claim 44 (depends on 43)

The dosage form of claim 43, wherein the dosage form provides the plasma concentration of hydrocodone within the therapeutic range but below toxic concentrations over a period of time of about 12 hours after administration to the human patient.

### Claim 45 (depends on 44)

The dosage form of claim 44, wherein said administration is first administration.

### Claim 46 (depends on 43)

The dosage form of claim 43, wherein said administration is first administration.

### Claim 47 (depends on 43)

The dosage form of claim 43, wherein the controlled release material comprises a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac and oils.

### Claim 48 (depends on 43)

The dosage form of claim 43, wherein the dosage form provides a C24/Cmax hydrocodone ratio of from about 0.55 to about 1 after said administration.

### Claim 49

A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a matrix comprising hydrocodone or a pharmaceutically acceptable salt thereof, a controlled release material and hydroxypropylcellulose or hydroxypropylmethylcellulose, such that the dosage form provides a Tmax of hydrocodone of from about 4 to about 14 hours and a plasma concentration of hydrocodone within a therapeutic range but below toxic concentrations over a period of time of about 12 hours or longer after administration to a human patient, wherein
the dosage form is a compressed tablet,
the amount of hydrocodone in the dosage form is from about 0.5 mg to about 1250 mg, and
the hydrocodone or a pharmaceutically acceptable salt thereof is the only active agent in the dosage form.

### Claim 50 (depends on 49)

The dosage form of claim 49, wherein the dosage form provides the plasma concentration of hydrocodone within the therapeutic range but below toxic concentrations over a period of time of about 12 hours after administration to the human patient.

### Claim 51 (depends on 50)

The dosage form of claim 50, wherein said administration is first administration.

### Claim 52 (depends on 49)

The dosage form of claim 49, wherein said administration is first administration.

### Claim 53 (depends on 49)

The dosage form of claim 49, wherein the dosage form provides a mean C24/Cmax hydrocodone ratio of from about 0.55 to about 1 after administration to a patient population.

### Claim 54 (depends on 49)

The dosage form of claim 49, wherein the dosage form provides a C24/Cmax hydrocodone ratio of from about 0.55 to about 1 after administration to the human patient.

### Claim 55 (depends on 49)

The dosage form of claim 49, wherein the controlled release material comprises a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac, and oils.

### Claim 56

A solid oral controlled-release dosage form of hydrocodone, the dosage form comprising a matrix comprising hydrocodone bitartrate, a controlled release material and hydroxypropylcellulose or hydroxypropylmethylcellulose, such that the dosage form provides a plasma concentration of hydrocodone within a therapeutic range but below toxic concentrations over a period of time of about 12 hours or longer after administration to a human patient, wherein
the dosage form is a compressed tablet,
the amount of hydrocodone bitartrate in the dosage form is equivalent to from about 0.5 mg to about 1250 mg hydrocodone, and
the hydrocodone bitartrate is the only active agent in the dosage form.

### Claim 57 (depends on 56)

The dosage form of claim 56, wherein the controlled release material comprises a material selected from the group consisting of gums, cellulose ethers, acrylic resins, waxes, shellac, and oils.

### Claim 58 (depends on 56)

The dosage form of claim 56, wherein the controlled release material comprises ethylcellulose.

### Claim 59 (depends on 56)

The dosage form of claim 56, wherein the dosage form provides a mean C24/Cmax hydrocodone ratio of from about 0.55 to about 1 after administration to a patient population.

### Claim 60 (depends on 39)

The dosage form of claim 39, wherein the controlled release material comprises ethylcellulose.

### Claim 61 (depends on 56)

The dosage form of claim 56, wherein the controlled release material is included in an effective amount such that the dosage form provides an in-vitro release of hydrocodone when measured by the USP Basket method at 100 rpm in 700 ml aqueous buffer at a pH of 1.2 at 37° C. of from 10% to about 45% by weight hydrocodone released at 1 hour.

### Claim 62 (depends on 56)

The dosage form of claim 56, wherein the dosage form provides the plasma concentration of hydrocodone within the therapeutic range but below toxic concentrations over a period of time of about 12 hours after administration to the human patient.

### Claim 63 (depends on 62)

The dosage form of claim 62, wherein said administration is first administration.

### Claim 64 (depends on 56)

The dosage form of claim 56, wherein said administration is first administration.

### Claim 65 (depends on 39)

The dosage form of claim 39, wherein the matrix comprises a granulation comprising the hydrocodone or pharmaceutically acceptable salt thereof and the hydroxypropylcellulose or hydroxypropylmethylcellulose.

### Claim 66 (depends on 39)

The dosage form of claim 39, wherein the dosage form provides a mean ratio of mean plasma concentrations of hydrocodone at the end of a dosing interval to mean maximum plasma concentrations of hydrocodone during the dosing interval of about 0.55 to about 1 after administration to a patient population.

### Claim 67 (depends on 56)

The dosage form of claim 56, which provides a C24/Cmax hydrocodone ratio of from about 0.55 to about 1 after said administration.

### Claim 68 (depends on 56)

The dosage form of claim 56, wherein the matrix comprises a granulation comprising the hydrocodone or pharmaceutically acceptable salt thereof and the hydroxypropylcellulose or hydroxypropylmethylcellulose.
